stockrowTriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024.
- Revenue
- +1.73%
- EPS
- +40.7%
- Free cash flow
- −41.3%
- Total debt
- +2.45%
Quarter to June 2026, against a year earlier
Follow TLSI
Alert me
TriSalus Life Sciences, Inc. (TLSI) EV/Sales
As of 5 November 2026, TriSalus Life Sciences, Inc. (TLSI) trades at a EV/Sales of 4.3×. Over the past ten years it has ranged from 0.0× (June 2023) to 10.8× (April 2024); the current reading is higher than 60% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.1× | 28.48% |
| FY2024 | 4.8× | 31.45% |
| FY2023 | 3.6× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.6× | 37.31% |
| Mar 2026 | 4.1× | (33.66%) |
| Dec 2025 | 6.1× | 17.32% |
| Sep 2025 | 5.2× | 1.69% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.5× |
| RXST RxSight, Inc. compare | −0.4× |
| TMCI Treace Medical Concepts, Inc. compare | 1.4× |
| STIM Neuronetics, Inc. compare | 1.5× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. compare | 2.7× |
| TLSI TriSalus Life Sciences, Inc. | 4.3× |
| PROF Profound Medical compare | 9.6× |
| QSI Quantum-Si Incorporated compare | 121× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)